HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Nizatidine (Axid)

A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

Also Known As:

Axid; LY-139037; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; LY 139037; LY139037; 1,1-Ethenediamine, N-(2-(((2-((dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-

Networked: 152 relevant articles (50 outcomes, 53 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kishi, Masahiko: 2 articles (02/2015 - 04/2014)
2.	Tateno, Akihiko: 2 articles (02/2015 - 04/2014)
3.	Hirai, Shigekazu: 2 articles (02/2015 - 04/2014)
4.	Ogata, Tsuyoshi: 2 articles (02/2015 - 04/2014)
5.	Doi, Hirokazu: 2 articles (02/2015 - 04/2014)
6.	Tateno, Fuyuki: 2 articles (02/2015 - 04/2014)
7.	Masaka, Tohru: 2 articles (02/2015 - 04/2014)
8.	Tsuyusaki, Yohei: 2 articles (02/2015 - 04/2014)
9.	Sakakibara, Ryuji: 2 articles (02/2015 - 04/2014)
10.	Sato, Mitsutoshi: 2 articles (02/2015 - 04/2014)

Related Diseases

1.	Duodenal Ulcer (Curling's Ulcer) 01/01/1987 - "Nizatidine proved to be safe and effective in preventing recurrences of duodenal ulcer." 03/01/1995 - "The aim of the present study was to assess the efficacy of a half-single nocturnal dose of nizatidine (150 mg at bedtime [h.s.], n = 40) with a standard full dose given once nightly (300 mg h.s., n = 38) or twice daily (150 mg twice a day [b.i.d.], n = 43) in the treatment of Chinese patients with active duodenal ulcers. " 01/01/1987 - "Nizatidine as maintenance therapy of duodenal ulcer disease in remission." 03/01/1995 - "Our study suggested that a half-single nocturnal dose of nizatidine is not ideal for the treatment of duodenal ulcer in Chinese patients, whereas a single standard nocturnal dose appears more effective than a twice-daily regimen." 01/01/1994 - "In duodenal ulcer (DU), the long-term nature of treatments and psychological status of patients make QoL studies of major interest, as exemplified by the nizatidine model."
2.	Gastroesophageal Reflux (GERD) 01/01/2008 - "We experienced a patient with gastroesophageal reflux disease (GERD) and impaired salivary secretion who has been successfully treated with nizatidine. " 02/01/2002 - "Increased salivary secretion and bicarbonate output induced by nizatidine may be useful for the treatment of patients with gastro-oesophageal reflux disease." 10/01/2010 - "Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease." 12/01/1999 - "Nizatidine appears to possess a prokinetic mechanism that may be helpful in treating patients with gastroesophageal reflux." 10/01/2010 - "The aim of the study is to test whether nizatidine delivered via a unique bimodal pulsatile-controlled release system, nizatidine controlled release (CR), accelerates gastric emptying in patients with gastroesophageal reflux disease (GERD). "
3.	Heartburn (Pyrosis) 11/01/1994 - "Compared with placebo, nizatidine 150 mg twice daily was highly effective in rapidly reducing the severity of heartburn, regardless of oesophagitis severity at entry. " 11/01/1994 - "Twice-daily administration of nizatidine 150 mg or 300 mg provides prompt relief from the major symptom of GORD, heartburn, and complete healing of oesophagitis is seen in many patients." 07/28/1997 - "Single doses of 225 mg and 75 mg of nizatidine administered 30 minutes before a standard meal intended to provoke heartburn are significantly more effective than placebo for the prevention and/or reduction of postprandial heartburn." 11/01/1994 - "The nizatidine 150 mg treatment group had significantly greater improvement in daytime and nighttime heartburn severity after 1 day of therapy versus placebo. " 06/01/1992 - "The nizatidine 150 mg treatment group had significantly greater improvement in daytime and nighttime heartburn severity after one day of therapy versus placebo. "
4.	Ulcer 01/01/1994 - "It is concluded that nizatidine is a safe and effective therapy for preventing DU recurrence in patients with endoscopically confirmed healed ulcers." 11/08/1993 - "This study showed that nizatidine, 150 mg, twice daily, significantly reduces the incidence of ulcer formation in high-risk patients taking long-term NSAID therapy. " 01/01/1992 - "[Modern trends in the treatment of ulcer disease (clinical study of nizatidine "Galitidine")]." 05/01/1995 - "Seven patients whose ulcer recurred after discontinuation of nizatidine were allocated to receive 2 weeks of triple therapy. " 10/01/1994 - "Nizatidine and placebo induced ulcer healing in 76% and 60.9% of the patients, respectively, but the difference did not reach statistical significance. "
5.	Weight Gain 07/01/2004 - "Nizatidine may be effective for reducing weight gain associated with both medical and psychiatric conditions. " 12/01/2006 - "Patients receiving placebo and nizatidine had a mean weight gain of 12.3% (0.7 kg) and 12% (1.1 kg) from baseline to endpoint, respectively (p = 0.9). " 07/01/2004 - "Based on a report of another patient who developed EPS after taking higher-than-recommended doses of nizatidine, we reviewed the literature on treatment with H2-receptor antagonists for weight gain and on central nervous system adverse effects of nizatidine. " 07/01/2004 - "Nizatidine, a histamine2 (H2)-receptor antagonist, may help reduce this weight gain. " 08/01/2003 - "A combination of nizatidine for 8 weeks resulted in significant reversal of weight gain without worsening the psychopathology (weight: 3.5% and BMI: 3.7%). "

Related Drugs and Biologics

1.	Ranitidine (Zantac)
2.	Cimetidine (Biomet)
3.	Famotidine (Pepcid)
4.	pantoprazole (Protonix)
5.	Histamine (Histamine Dihydrochloride)
6.	olanzapine (Zyprexa)
7.	Omeprazole (Esomeprazole)
8.	Leptin
9.	Cisapride (Propulsid)
10.	Acetylcholine (Acetylcholine Chloride)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Oral Administration
3.	Renal Dialysis (Hemodialysis)
4.	Ligation
5.	Electrodes (Electrode)